The efficacy and safety of perioperative antiplatelet therapy

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Surgical Management

Background:

• Antiplatelet agents significantly reduce major adverse cardiovascular events in various cardiovascular conditions.
• A growing number of patients on antiplatelet therapy require surgical procedures, necessitating perioperative management strategies.
• Understanding the risks and benefits of antiplatelet drugs during the perioperative period is increasingly important.

Purpose of the Study:

• To review the perioperative safety and efficacy of commonly used antiplatelet agents.
• To provide guidance for clinicians managing antiplatelet therapy around cardiac and noncardiac surgeries.

Main Methods:

• Review of available data on the perioperative use of aspirin, clopidogrel, and glycoprotein (GP) IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban).
• Examination of evidence regarding the safety and efficacy of these agents in surgical settings.
• Consideration of emerging platelet monitoring techniques.

Main Results:

• Data suggest that antiplatelet agents can be used safely prior to surgery when managed appropriately.
• Evidence supports the efficacy of these agents in improving surgical outcomes and preventing postoperative cardiovascular events.
• The review consolidates information on specific agents, including aspirin, clopidogrel, and GP IIb/IIIa inhibitors.

Conclusions:

• Appropriate perioperative management of antiplatelet therapy is feasible and beneficial.
• This information, combined with platelet monitoring, can assist clinicians in timing surgeries for patients on antiplatelet agents.
• Safe and effective use of antiplatelet agents perioperatively is achievable, balancing cardiovascular protection with surgical considerations.